Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

血管内皮细胞和内皮细胞释放的活性因子是调控血管舒张功能的重要因素. 糖尿病是慢性心血管
疾病的高危因素之一. 目前认为高糖和糖尿病引起的内皮细胞功能障碍是造成血管功能改变 …

Background Sparsentan is a novel, non-immunosuppressive, single-molecule, dual
endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial …

Loss of normal kidney function affects more than 10% of the population and contributes to
morbidity and mortality. Kidney diseases are currently treated with immunosuppressive …

Albuminuria is the hallmark of both primary and secondary proteinuric glomerulopathies,
including focal segmental glomerulosclerosis (FSGS), obesity-related nephropathy, and …

The kidney harbours different types of endothelia, each with specific structural and functional
characteristics. The glomerular endothelium, which is highly fenestrated and covered by a …

Background Short-term treatment for people with type 2 diabetes using a low dose of the
selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing …

Introduction: Diabetic kidney disease (DKD) is a major cause of morbidity and mortality in
diabetes and is the most common cause of proteinuric and non-proteinuric forms of end …

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), with
prevalence increasing at an alarming rate worldwide and today, there are no known cures …